Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Mechanisms of Proteasome Inhibitor Resistance Selected By Clonal Evolution in Multiple Myeloma

Larissa Haertle, PhD, Santiago Barrio, PhD, Michal Simicek, PhD, Umair Munawar, MSc, Ricardo Sanchez, PhD MD, Max Bittrich, MD, Matteo DaVia, MD, Cornelia Vogt, MSc, Nicola Giesen, MD, Andoni Garitano-Trojaola, PhD, Silvia Nerreter, Thorsten Stuehmer, PhD, Marc S. Raab, MD, Joaquin Martinez Lopez, MD PhD, Roman Hajek, MD, Hermann Einsele, MD, Leo Rasche, MD, Thomas Haaf, MD, Martin Kortüm, MD

Blood (2019) 134 (Supplement_1): 4349.

https://doi.org/10.1182/blood-2019-130847

Published: 2019

Journal Articles

Increase of Mitochondrial Activity Contributes to the Bortezomib-Relapsed in Multiple Myeloma, a Novel Therapeutic Opportunity

Alejandra Ortiz-Ruiz, BSc, Yanira Ruiz-Heredia, Mehmet Samur, PhD, Pedro Aguilar-Garrido, Maria Luz Morales, Antonio Valeri, PhD, Almudena Garcia-Ortiz, PhD, Santiago Barrio, PhD, Carmen Bárcena, Rosa Maria Garcia-Martin, Vanesa Garrido, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD, María Teresa Cedena, Joaquin Martinez-Lopez, MD PhD, Maria Linares, PhD, Miguel Gallardo, PhD

Blood (2019) 134 (Supplement_1): 4408.

https://doi.org/10.1182/blood-2019-123950

Published: 2019

Journal Articles

Clonal Competition Models to Understand Progression and Resistance in Myeloma

Santiago Barrio, PhD, Larissa Haertle, PhD, Umair Munawar, MSc, Lucia Martin, Isabel Cuenca, MSc, Cornelia Vogt, MSc, Andoni Garitano-Trojaola, PhD, Matteo Claudio Da Via', MD, Miguel Gallardo, PhD, Thorsten Stuehmer, PhD, Hermann Einsele, MD, Leo Rasche, MD, Joaquin Martinez-Lopez, MD PhD, Martin Kortüm, MD

Blood (2019) 134 (Supplement_1): 1807.

https://doi.org/10.1182/blood-2019-130812

Published: 2019

Journal Articles

Genetic Profiling and Novel Recurrent Chromosomal Alterations in Patients with Light Chain Amyloidosis

Blood (2018) 132 (Supplement 1): 4488.

https://doi.org/10.1182/blood-2018-99-114543

Published: 2018

Journal Articles

Implications of TP53 alterations for Therapy Response in Multiple Myeloma

Umair Munawar, MS, BS, Santiago Barrio, PhD, Markus Roth, Hermann Einsele, MD, Ralf C Bargou, Thorsten Stuehmer, Martin Kortum, MD

Blood (2018) 132 (Supplement 1): 3189.

https://doi.org/10.1182/blood-2018-99-118658

Published: 2018

Journal Articles

CIC-Mutation As a Potential Molecular Mechanism of Acquired Resistance to Combined BRAF/MEK Inhibition in CNS Multiple Myeloma

Matteo Claudio Da Via', MD, Antonio Giovanni Solimando, MD, Andoni Garitano-Trojaola, PhD, Santiago Barrio, PhD, Nadine Rodhes, Susanne Strifler, MD, Eva Teufel, Constantin Lapa, MD, Hermann Einsele, MD, Andreas Beilhack, MD, K. Martin Kortüm, MD

Blood (2018) 132 (Supplement 1): 3181.

https://doi.org/10.1182/blood-2018-99-117203

Published: 2018

Journal Articles

5q+ MDS Patients with Low RPS14 Expression Are Candidates to Immune-Modulating Drugs

María Linares, PhD, Inmaculada Rapado, Yanira Ruiz-Heredia, Maria Teresa Cedena, Keina Quiroz, Santiago Barrio, PhD, Rosa Ayala, Joaquín Martínez

Blood (2017) 130 (Supplement 1): 5303.

https://doi.org/10.1182/blood.V130.Suppl_1.5303.5303

Published: 2017

Journal Articles

Targeted Deep Sequencing in Untreated Progressive CLL Helps to Better Dissect the Genomic Landscape and Shows Novel Associations between Mutations, Prognostic and Clinical Parameters: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

Esteban Braggio, PhD, Victoria Wang, Laura Ann Bruins, BS, Santiago Barrio, PhD, Connie Lesnick, Jacqueline C. Barrientos, MD, Susan M. O'Brien, MD, Martin S. Tallman, MD, Mark R. Litzow, MD, Rafael Fonseca, MD, Neil E. Kay, MD, Tait D Shanafelt, MD

Blood (2017) 130 (Supplement 1): 4288.

https://doi.org/10.1182/blood.V130.Suppl_1.4288.4288

Published: 2017

Journal Articles

Parallel Evolution of Multiple PSMB5 mutations in a Myeloma Patient Treated with Bortezomib

Santiago Barrio, PhD, Thorsten Stühmer, PhD, Eva Teufel, Clara Barrio-Garcia, Manik Chatterjee, MD, Martin Schreder, MD, Mithun Das Gupta, MD, Andreas Rosenwald, MD, Raoul Tibes, MD PhD, Esteban Braggio, PhD, A. Keith Stewart, MD, Ralf C Bargou, MD, Hermann Einsele, MD, K Martin Kortüm, MD

Blood (2016) 128 (22): 3282.

https://doi.org/10.1182/blood.V128.22.3282.3282

Published: 2016

Journal Articles

Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma Patients

Beatriz Sanchez-Vega, PhD, Rafael Alonso, MD, Isabel Cuenca, Santiago Barrio, PhD, Yanira Ruiz-Heredia, Carlos Marin, Inmaculada Rapado, PhD, Cristina Jimenez, BSc, Xabier Aguirre, Rosa M. Ayala, MD PhD, Teresa Cedena, Bruno Paiva, PhD, Maria-Victoria Mateos, MD PhD, Laura Rosiñol, Joan Bladé, Jesus San Miguel, MD PhD, Ramon Garcia-Sanz, MD PhD, Juan José Lahuerta, MDPhD, Joaquín Martínez-López, MD PhD

Blood (2016) 128 (22): 3283.

https://doi.org/10.1182/blood.V128.22.3283.3283

Published: 2016

Journal Articles

High Throughput Screening, With a Flow Cytometry Automated Platform (Ex vivo Biotech), To Identify Potential Combination Partners, For The JAK 2 Inhibitor Ruxolitinib

Alicia Arenas, Pilar Hernandez-Campo, Daniel Primo, Santiago Barrio, PhD, Rosa M. Ayala, MD, PhD, Joan Ballesteros, Joaquín Martínez-López, MD, PhD

Blood (2013) 122 (21): 2534.

https://doi.org/10.1182/blood.V122.21.2534.2534

Published: 2013

Journal Articles

Prognostic Value Of Deep Sequencing Approach For Minimal Residual Disease (MRD) Detection In Multiple Myeloma Patients

Blood (2013) 122 (21): 1848.

https://doi.org/10.1182/blood.V122.21.1848.1848

Published: 2013

Journal Articles

Sensitivity, Reproducibility and Clinical Utility Of Next-Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain Mutation Screening: Results From The CML Work Package Of The Iron-II (Interlaboratory RObustness Of Next-Generation Sequencing) International Study

Blood (2013) 122 (21): 3824.

https://doi.org/10.1182/blood.V122.21.3824.3824

Published: 2013

Journal Articles

Deep Sequencing Reveals Oligoclonality At The Immunoglobulin Locus In Multiple Myeloma Patients

Joaquin Martinez-Lopez, MD, PhD, Mariateresa Fulciniti, PhD, Santiago Barrio, PhD, Victoria Carlton, PhD, Martin Moorhead, PhD, Juan Jose Lahuerta, MD, Kenneth C. Anderson, MD, Florence Magrangeas, Stephane Minvielle, PhD, Herve Avet-loiseau, Malek Faham, MD, PhD, Nikhil C. Munshi, MD

Blood (2013) 122 (21): 401.

https://doi.org/10.1182/blood.V122.21.401.401

Published: 2013

NARROW

Mechanisms of Proteasome Inhibitor Resistance Selected By Clonal Evolution in Multiple Myeloma

Increase of Mitochondrial Activity Contributes to the Bortezomib-Relapsed in Multiple Myeloma, a Novel Therapeutic Opportunity

Clonal Competition Models to Understand Progression and Resistance in Myeloma

Genetic Profiling and Novel Recurrent Chromosomal Alterations in Patients with Light Chain Amyloidosis

Implications of TP53 alterations for Therapy Response in Multiple Myeloma

CIC-Mutation As a Potential Molecular Mechanism of Acquired Resistance to Combined BRAF/MEK Inhibition in CNS Multiple Myeloma

5q+ MDS Patients with Low RPS14 Expression Are Candidates to Immune-Modulating Drugs

Targeted Deep Sequencing in Untreated Progressive CLL Helps to Better Dissect the Genomic Landscape and Shows Novel Associations between Mutations, Prognostic and Clinical Parameters: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

Parallel Evolution of Multiple PSMB5 mutations in a Myeloma Patient Treated with Bortezomib

Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma Patients

High Throughput Screening, With a Flow Cytometry Automated Platform (Ex vivo Biotech), To Identify Potential Combination Partners, For The JAK 2 Inhibitor Ruxolitinib

Prognostic Value Of Deep Sequencing Approach For Minimal Residual Disease (MRD) Detection In Multiple Myeloma Patients

Sensitivity, Reproducibility and Clinical Utility Of Next-Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain Mutation Screening: Results From The CML Work Package Of The Iron-II (Interlaboratory RObustness Of Next-Generation Sequencing) International Study

Deep Sequencing Reveals Oligoclonality At The Immunoglobulin Locus In Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only